Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial

  title={Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial},
  author={Salim Abdulla and Issaka Sagara and Steffen Borrmann and Umberto d’Alessandro and Raquel Gonz{\'a}lez and Mary J. Hamel and Bernhards Ogutu and Andreas M{\aa}rtensson and John Lyimo and Hamma Maiga and Philip Galula Sasi and Alain Nahum and Quique Bassat and Elizabeth A. Juma and Lucas Otieno and Anders Björkman and Hans-Peter Beck and Kim Andriano and Marc Cousin and Gilbert Y. Lef{\`e}vre and David Ubben and Zulfikar Premji},
  journal={The Lancet},

Figures and Tables from this paper

Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children

Ahead of a call from WHO for child-friendly medicines, Novartis started the development of a new formulation of AL for infants and young children: Coartem® Dispersible, whose sweet taste means that it is palatable for children, and the dispersible formulation makes it easier for caregivers to administer than bitter crushed tablets.

Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study

AL and DP were both efficacious and well tolerated, and had similar effects at day 42 on risk of recurrent malaria.

Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®)

A three-day regimen of AL dispersible formulation was efficacious and generally well tolerated in infants weighing <5 kg with uncomplicated P. falciparum malaria, but artemether and dihydroartemisinin exposures could not be supported by the preclinical safety margins for neurotoxicity.

Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges

Efficacy of AL in uncomplicated falciparum malaria is similar across body weight dosing groups as currently recommended in the label with no clinically relevant differences in safety or tolerability.

Artemether-lumefantrine: Pediatric formulations for the treatment of uncomplicated Plasmodium falciparum

There is a clear unmet medical need for a formulation of Artemether/lumefantrine specifically designed for infants and children in all age groups.

Tolerability and Efficacy of a Pediatric Granule Formulation of Artesunate-Mefloquine in Young Children from Cameroon with Uncomplicated Falciparum Malaria

The new formulation of artesunate and mefloquine (Artequin Pediatric) was well tolerated and efficacious in the population investigated and determined by survival analysis at 28 and 63 days was 96.6%.

Randomized Trial of Safety and Effectiveness of Chlorproguanil-Dapsone and Lumefantrine-Artemether for Uncomplicated Malaria in Children in The Gambia

AL was well tolerated and highly effective and when given under operational conditions despite poor adherence to the six-dose regimen, and there were more cases of severe malaria and anaemia after CD treatment although G6PD deficiency was uncommon.

Pharmacokinetic and Pharmacodynamic Characteristics of a New Pediatric Formulation of Artemether-Lumefantrine in African Children with Uncomplicated Plasmodium falciparum Malaria (cid:1)

The results suggest that the dispersible tablet provides adequate systemic exposure to artemether, DHA, and lumefantrine in African children with uncomplicated P. falciparum malaria.

The clinical efficacy of artemether/lumefantrine (Coartem®)

The efficacy of the six-dose regimen of artemether/lumefantrine has been confirmed in many different patient populations around the world, consistently achieving 28-day PCR-corrected cure rates of >95% in the evaluable population, rapidly clearing parasitaemia and fever, and demonstrating a significant gametocidal effect, even in areas of widespread parasite resistance to other antimalarials.



Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.

Both treatments were highly efficacious, but AL provided stronger prevention against reinfection and the genetic selection by the long-acting partner drug underlines the importance of long follow-up periods in clinical trials.

Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda.

The high adherence to artemether-lumefantrine found in this study suggest that this drug is likely to be very effective in Mbarara provided that patients receive clear dosage explanations.

Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data.

The main finding of this analysis is that the six- dose regimen of coartemether is safe and more efficacious than the four-dose regimen in children.

Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives.

Oral artesunate and artemether alone were very well tolerated and there was no difference in the incidence of possible adverse effects between the two drugs, and no evidence that either derivative caused allergic reactions, neurologic or psychiatric reactions, or cardiovascular or dermatologic toxicity.

Artemisinin-based combinations

A once daily three-dose treatment of dihydroartemisinin piperaquine was a highly efficacious and well tolerated treatment for multi-drug resistant falciparum malaria in Southeast Asia.